Interviews

Masatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.

Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.

Jonathon B. Cohen, MD, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine and rituximab in patients with aggressive lymphomas.

David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia.

<br /> Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the current treatment landscape for liver cancer and the advances seen over the last decade at the 2018 International Liver Cancer Association Annual Conference.

Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.

Michael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer.

Kamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia. After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.

Gabriela S. Hobbs, MD, clinical director of the Leukemia Service and assistant in medicine at Massachusetts General Hospital, shares her advice for a community oncologist treating a patient with chronic myeloid leukemia.

Karen Reckamp, MD, co-director of the Thoracic Oncology Program at the City of Hope Comprehensive Cancer Center, discusses combinations with immunotherapy in lung cancer at the International Lung Cancer Congress. She says this is a very hot topic in the field right now.

Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke&rsquo;s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.

Jacqueline D. Barrientos, MD, MS,&nbsp;associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma, as well as the challenges investigators still face in the field.

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing on&nbsp;<em>ROS1&nbsp;</em>and&nbsp;<em>TRK&nbsp;</em>mutations.

Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.

Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.&nbsp;

David O&rsquo;Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the biggest challenge in treating patients with chronic lymphocytic leukemia.

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma that should receive adjuvant sunitinib therapy.&nbsp;

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the unique adverse events with immunotherapy agents and how physicians can work together to overcome these challenges.

Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term&nbsp;treatment&nbsp;strategy for&nbsp;reducing tumor burden and the risk for tumor lysis syndrome in patients with&nbsp;chronic lymphocytic leukemia.

John L. Marshall, MD, chief of the&nbsp; Division of Hematology/Oncology at Medstar Georgetown University Hospital, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the use of chemotherapy in patients with colorectal or other gastrointestinal cancers. He also highlights the importance of understanding each individual patient&rsquo;s needs before making a treatment decision.&nbsp;

Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br /> &nbsp;

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.&nbsp;

Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.